Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

LIPO

Lipella Pharmaceuticals (LIPO)

Lipella Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:LIPO
DateTimeSourceHeadlineSymbolCompany
05/31/20248:00AMGlobeNewswire Inc.Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen PlanusNASDAQ:LIPOLipella Pharmaceuticals Inc
05/29/20248:00AMGlobeNewswire Inc.Lipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:LIPOLipella Pharmaceuticals Inc
05/21/20248:00AMGlobeNewswire Inc.Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2bNASDAQ:LIPOLipella Pharmaceuticals Inc
05/15/20244:39PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LIPOLipella Pharmaceuticals Inc
05/09/20244:06PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LIPOLipella Pharmaceuticals Inc
05/06/20244:05PMEdgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:LIPOLipella Pharmaceuticals Inc
04/17/20248:00AMGlobeNewswire Inc.Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology ExpertiseNASDAQ:LIPOLipella Pharmaceuticals Inc
04/05/20248:00AMGlobeNewswire Inc.Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024NASDAQ:LIPOLipella Pharmaceuticals Inc
04/03/20248:00AMGlobeNewswire Inc.Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic CystitisNASDAQ:LIPOLipella Pharmaceuticals Inc
03/07/20243:23PMGlobeNewswire Inc.PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare DiseaseNASDAQ:LIPOLipella Pharmaceuticals Inc
03/06/20245:05PMEdgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:LIPOLipella Pharmaceuticals Inc
03/06/20245:03PMEdgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:LIPOLipella Pharmaceuticals Inc
03/05/20248:00AMGlobeNewswire Inc.Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical PipelineNASDAQ:LIPOLipella Pharmaceuticals Inc
02/27/20245:04PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:LIPOLipella Pharmaceuticals Inc
02/27/20244:51PMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:LIPOLipella Pharmaceuticals Inc
02/20/20248:00AMGlobeNewswire Inc.Lipella Pharmaceuticals to Present at PropThink Digital Investor ConferenceNASDAQ:LIPOLipella Pharmaceuticals Inc
02/09/202412:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LIPOLipella Pharmaceuticals Inc
02/07/20245:29PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:LIPOLipella Pharmaceuticals Inc
02/01/20244:09PMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:LIPOLipella Pharmaceuticals Inc
01/25/20244:06PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:LIPOLipella Pharmaceuticals Inc
01/03/20244:59PMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:LIPOLipella Pharmaceuticals Inc
12/20/20238:00AMGlobeNewswire Inc.Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones AccomplishedNASDAQ:LIPOLipella Pharmaceuticals Inc
11/28/20235:28PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIPOLipella Pharmaceuticals Inc
11/22/20234:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIPOLipella Pharmaceuticals Inc
11/14/20236:22AMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:LIPOLipella Pharmaceuticals Inc
11/14/20236:14AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LIPOLipella Pharmaceuticals Inc
11/10/20238:00AMPR Newswire (US)FDA Grants Orphan Designation for Lipella's LP-310 Drug Candidate for Oral Graft-versus-Host DiseaseNASDAQ:LIPOLipella Pharmaceuticals Inc
11/09/20234:07PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:LIPOLipella Pharmaceuticals Inc
11/09/202312:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LIPOLipella Pharmaceuticals Inc
11/07/20235:22PMEdgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:LIPOLipella Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:LIPO